Effects of resveratrol on the anthropometric indices and inflammatory markers: an umbrella meta-analysis

The evidence for resveratrol's anti-obesity and anti-inflammatory qualities is accumulating, though meta-analyses have reported mixed results. The current umbrella meta-analysis aimed to assess the present evidence and provide an accurate estimate of the overall effects of resveratrol on the anthropometric indices and inflammatory markers.

The Web of Science, PubMed, Scopus, and Google Scholar databases were searched till March 2023. The meta-analysis was performed utilizing a random-effects model. Moreover, the overall strength and quality of the evidence were assessed using the GRADE tool.

The results from 19 meta-analyses investigating 81 unique randomized controlled trials with 4088 participants revealed that resveratrol supplementation reduced the body mass index (ES =  − 0.119, 95% CI (− 0.192, − 0.047), p = 0.001), waist circumference (ES =  − 0.405, 95% CI [− 0.664, − 0.147], p = 0.002), serum levels of C-reactive protein (ES =  − 0.390, 95% CI [− 0.474, − 0.306], p < 0.001), and tumor necrosis factor-α (ES =  − 0.455, 95% CI [− 0.592, − 0.318], p < 0.001) in comparison to the control group. The effects of resveratrol on body weight and Interleukin-6 levels of participants were not significant. However, resveratrol administration significantly decreased body weight in trials with intervention duration ≥ 12 weeks [ES =  − 0.160, 95% CI (− 0.268, − 0.052)] and supplement dosage ≥ 500 mg/day [ES =  − 0.130, 95% CI (− 0.238, − 0.022)].

The findings suggest the beneficial effects of resveratrol supplementation on reducing general and central obesity, as well as decreasing some inflammatory markers. Nevertheless, further high-quality research is required to prove these achievements and also evaluate resveratrol's effects on other inflammatory markers.